Dr. Konrad Aden, Senior Clinician Scientist at the Cluster of Excellence PMI and specialist in internal medicine in Kiel, has been awarded one of three publication prizes for 2022 by the Else Kröner-Fresenius Foundation.
With the publication prize for 2022, the Else Kröner-Fresenius Foundation (EKFS) honors early-stage researchers for their outstanding publications, which have been produced with funding from the foundation. Each of the prizes is endowed with 10,000 Euros for use at the prizewinner’s private discretion. One of this year's winners is PD Dr. Konrad Aden. He is a senior consultant at the Department of Internal Medicine I at the University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, working group head at the Institute of Clinical Molecular Biology (IKMB) at the UKSH and Kiel University (CAU) and member of the Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI). In 2021, Aden was appointed to the renowned Else Kröner Clinician Scientist Professorship, which enables him to carry out his ambitious clinical-related research on the causes and mechanisms of chronic inflammatory bowel diseases in addition to patient care in the hospital.
The scientist has been honored for a publication in the renowned scientific journal "Gastroenterology" (https://pubmed.ncbi.nlm.nih.gov/34599932/). In this paper, the research team led by Aden discovered a novel mechanism that can interfere with DNA repair in people with chronic intestinal inflammation and thus lead to bowel cancer. It has long been known that cancer can develop from chronic intestinal inflammation. However, precisely how this occurs has hardly been researched. The present study was able to demonstrate a new link between inflammation, disturbed cell division and repair of the genetic material. Further studies will be conducted on this basis to examine how the new findings can be used for the prevention of bowel cancer.
- How chronic intestinal inflammation can cause cancer (Press release from 20.10.2021)
Link to the Else Kröner-Fresenius Foundation:
Welz L, Kakavand N, Hang X, Laue G, Ito G, Silva MG, Plattner C, Mishra N, Tengen F, Ogris F, Jesinghaus M, Wottawa F, Arnold P, Kaikkonen L, Stengel S, Tran F, Das S, Kaser A, Trajanoski Z, Blumberg R, Roecken C, Saur D, Tschurtschenthaler M, Schreiber S, Rosenstiel P and Aden K. Epithelial XBP1 coordinates TP 53-driven DNA damage responses and suppression of intestinal carcinogenesis. Gastroenterology (2021)
About the Cluster of Excellence PMI
The Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI) is being funded from 2019 to 2025 through the German Excellence Strategy (ExStra). It succeeds the "Inflammation at Interfaces” Cluster, which was already funded in two periods of the Excellence Initiative (2007-2018). Around 300 members from eight institutions at four locations are involved: Kiel (Kiel University, University Medical Center Schleswig-Holstein (UKSH), Muthesius University of Fine Arts and Design, Kiel Institute for the World Economy (IfW), Leibniz Institute for Science and Mathematics Education (IPN)), Lübeck (University of Lübeck, University Medical Center Schleswig-Holstein (UKSH)), Plön (Max Planck Institute for Evolutionary Biology) and Borstel (Research Center Borstel - Leibniz Lung Center).
The goal is to translate interdisciplinary research findings on chronic inflammatory diseases of barrier organs to healthcare more intensively, as well as to fulfil previously unsatisfied needs of the patients. Three points are important in the context of successful treatment, and are therefore at the heart of PMI research: the early detection of chronic inflammatory diseases, the prediction of disease progression and complications, and the prediction of individual responses to treatment.
email@example.com+49 431 880-4682